Pyrithyldione

Chemical compound
  • N05CE03 (WHO)
Identifiers
  • 3,3-diethylpyridine-2,4(1H,3H)-dione
CAS Number
  • 77-04-3 ☒N
PubChem CID
  • 4994
ChemSpider
  • 4820 checkY
UNII
  • 8AB20823CK
KEGG
  • D07329 checkY
ChEMBL
  • ChEMBL1722501 ☒N
CompTox Dashboard (EPA)
  • DTXSID4045262 Edit this at Wikidata
ECHA InfoCard100.000.910 Edit this at WikidataChemical and physical dataFormulaC9H13NO2Molar mass167.208 g·mol−13D model (JSmol)
  • Interactive image
  • O=C1N/C=C\C(=O)C1(CC)CC
InChI
  • InChI=1S/C9H13NO2/c1-3-9(4-2)7(11)5-6-10-8(9)12/h5-6H,3-4H2,1-2H3,(H,10,12) checkY
  • Key:NZASCBIBXNPDMH-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Pyrithyldione[1] (Presidon, Persedon) is a psychoactive drug invented in 1949.[2] An improved method of manufacture was patented by Roche in 1959.[3] It was used as a hypnotic or sedative and presumed to be less toxic than barbiturates.[4] Today, this substance is no longer used. Agranulocytosis was sometimes reported as adverse effect.[5][6] Pyrithyldione is also a CYP2D6 inducer but is not as potent as glutethimide.[7] In studies, it increased the O-demethylation of codeine by 20%.

See also

References

  1. ^ US Patent 2090068 - 2,4-Dioxo-3,3-Dialkyl-Tetrahydropyridines and Process for the Manufacture of Same.
  2. ^ Becker EL, Fabing HD, Hawkins JR (April 1949). "Presidon; a new sedative-hypnotic". Christ Hospital Medical Bulletin. 2 (4): 80–4. PMID 18144514.
  3. ^ US patent 3019230, Hinderling R, Lutz AH, Schnider O, "Method for the preparation of 2,4-dioxo-tetrahydropyridines", issued 1962-01-30, assigned to Hoffmann-La Roche 
  4. ^ Pribilla, O. (1956). "Zur Toxikologie des Persedons". Archiv für Toxikologie. 16 (1): 34–49. doi:10.1007/BF00577351. S2CID 38210598.
  5. ^ Ibáñez L, Ballarín E, Pérez E, Vidal X, Capellà D, Laporte JR (January 2000). "Agranulocytosis induced by pyrithyldione, a sedative hypnotic drug". European Journal of Clinical Pharmacology. 55 (10): 761–4. doi:10.1007/s002280050011. PMID 10663456. S2CID 25595314.
  6. ^ Covner AH, Halpern SL (January 1950). "Fatal agranulocytosis following therapy with presidon (3,3-diethyl-2,4-dioxotetrahydropyridine) a new sedative hypnotic agent". The New England Journal of Medicine. 242 (2): 49–52. doi:10.1056/NEJM195001122420203. PMID 15399031.
  7. ^ [Is pyrithyldione (Benedorm) an enzyme inducer (author's transl)] Pharmazie. 1982 Jan;37(1):69.
  • v
  • t
  • e
GABAA
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Imidazoles
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Quinazolinones
Others
GABABH1
Antihistamines
Antidepressants
Antipsychotics
α2-Adrenergic5-HT2A
Antidepressants
Antipsychotics
Others
MelatoninOrexinα2δ VDCCOthers
  • v
  • t
  • e
GABAA receptor positive modulators
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Flavonoids
Imidazoles
Kava constituents
  • 10-Methoxyyangonin
  • 11-Methoxyyangonin
  • 11-Hydroxyyangonin
  • Desmethoxyyangonin
  • 11-Methoxy-12-hydroxydehydrokavain
  • 7,8-Dihydroyangonin
  • Kavain
  • 5-Hydroxykavain
  • 5,6-Dihydroyangonin
  • 7,8-Dihydrokavain
  • 5,6,7,8-Tetrahydroyangonin
  • 5,6-Dehydromethysticin
  • Methysticin
  • 7,8-Dihydromethysticin
  • Yangonin
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Pyrazolopyridines
Quinazolinones
Volatiles/gases
Others/unsorted
  • Unsorted benzodiazepine site positive modulators: α-Pinene
  • MRK-409 (MK-0343)
  • TCS-1105
  • TCS-1205
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators
Stub icon

This sedative-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e